Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

BLA for Zevalin granted priority review by FDA

Jan. 3, 2001

Genta licenses technology platform for designing novel anticancer treatments

Jan. 3, 2001

Bioniche bladder cancer trial yields positive interim results

Jan. 3, 2001

Enhanced version of MetXia to be codeveloped by Oxford BioMedica and PolyMASC

Jan. 3, 2001

Clinical trial commences for new antiangiogenic agent discovered by OSI and Pfizer

Jan. 2, 2001

BresaGen's lead anticancer compound E21R licensed to British Biotech

Jan. 2, 2001

Enzon seeks FDA approval to clinically evaluate PEG-paclitaxel

Jan. 2, 2001

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Jan. 2, 2001

Gilead's NX-211 enters phase II for second cancer indication

Dec. 29, 2000

Sumitomo licenses class of DACH platinum compounds to Aronex

Dec. 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.